A Randomized, Open-Label, Single-Dose, 2-Period, Crossover Design, Phase 1 Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 T2 Tablet Formulation in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 19 May 2017
At a glance
- Drugs TAK 831 (Primary)
- Indications Ataxia; Schizophrenia
- Focus Pharmacokinetics
- Sponsors Takeda
- 16 May 2017 Planned End Date changed from 18 May 2017 to 24 May 2017.
- 16 May 2017 Planned primary completion date changed from 11 May 2017 to 19 May 2017.
- 07 Apr 2017 New trial record